AI Article Synopsis
- Intravenous tPA is the standard treatment for acute ischemic stroke, leading to effective outcomes, but comes with risks of serious complications.
- A 72-year-old male developed facial angioedema shortly after receiving tPA, requiring antihistamine and steroid treatment for symptom relief.
- This case underscores the importance of monitoring tPA patients closely and suggests a need for more research on preventing tPA-induced angioedema.
Article Abstract
Intravenous tissue plasminogen activator (tPA) remains the standard of treatment for patients presenting with acute ischemic stroke within the treatment window. In most patients, this often leads to an effective and life-prolonging intervention in the acute setting. This is, however, not without complications, which sometimes could be potentially fatal. Hemorrhagic complications, such as hemorrhagic conversion and bleeding, are the most discussed; however, facial angioedema has also been reported. We present a case of a 72-year-old African American male who developed right-sided ipsilateral orolingual angioedema 20 minutes after starting a tPA infusion. He was subsequently managed with antihistamine medications and steroids with interval resolution of symptoms. This case highlights the need for close monitoring while on tPA infusion, early detection, and management of potential facial angioedema complications. It also serves as a template for further studies focusing on preventative strategies for tPA-induced angioedema.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166123 | PMC |
| http://dx.doi.org/10.7759/cureus.38714 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ipsilateral orolingual angioedema following rhTNK-tPA administration for acute ischemic stroke.
Am J Emerg Med
March 2024
Department of Neurology, Taixing People's Hospital, Taixing, Jiangsu 225400, China. Electronic address:
Recombinant human tenecteplase tissue-type plasminogen activator (rhTNK-tPA), a genetically modified variant of conventional alteplase with longer half-life and higher fibrin specificity, has now emerged as a reasonable choice for thrombolytic treatment of acute ischemic stroke (AIS) in China. Orolingual angioedema is a rare but potentially life-threatening complication of intravenous thrombolysis. Currently, there is no documented evidence of orolingual angioedema occurring after thrombolysis with rhTNK-tPA.
View Article and Find Full Text PDFIpsilateral Orolingual Angioedema Following Alteplase Administration for the Treatment of Suspected Acute Ischemic Stroke.
Cureus
May 2023
Internal Medicine, Meharry Medical College, Nashville, USA.
Article Synopsis
- Intravenous tPA is the standard treatment for acute ischemic stroke, leading to effective outcomes, but comes with risks of serious complications.
- A 72-year-old male developed facial angioedema shortly after receiving tPA, requiring antihistamine and steroid treatment for symptom relief.
- This case underscores the importance of monitoring tPA patients closely and suggests a need for more research on preventing tPA-induced angioedema.
Orolingual angiodema associated with alteplase treatment of acute stroke: a reappraisal.
J Stroke Cerebrovasc Dis
January 2015
Stroke Unit, Hospital S. Francisco Xavier (Centro Hospitalar Lisboa Ocidental), Lisbon, Portugal; Neurology Department, Hospital Egas Moniz (Centro Hospitalar Lisboa Ocidental), Lisbon, Portugal; CEDOC (Chronic Diseases Research Center), Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal. Electronic address:
Background: Orolingual angioedema has been increasingly recognized as a potentially life-threatening complication associated with alteplase treatment of stroke. Concomitant treatment with an angiotension converting enzyme inhibitor (ACEi) and localization of infarction in the territory of middle cerebral artery seem to be associated with a higher risk of this complication.
Methods: We report the cases of orolingual angioedema among the patients undergoing alteplase treatment in our Stroke Unit.
Rationale: Post-intravenous recombinant tissue plasminogen activator (r-tPA) orolingual angioedema (PIROLA), including the life-threatening form, is an underappreciated complication of ischaemic stroke treatment.
Aims: We present an audit report and a systematic review of published observational studies on PIROLA occurrence in acute ischaemic stroke patients.
Methods: Clinical files of patients treated in the stroke unit of Bourg-en-Bresse General Hospital (France) from January 2010 to December 2012 were reviewed, and MEDLINE (inception to May 2013) were searched and bibliographies/citations of retrieved articles examined for evidence of PIROLA.
Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
Exp Neurol
December 2013
INGENIO, IRCE, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS-CELLEX), Barcelona, Spain; Centro de Investigación en Redes sobre Enfermedades Neurodegenerativas (CIBERNED), Spain. Electronic address:
The subthalamic nucleus (STN) receives direct dopaminergic innervation from the substantia nigra pars compacta that degenerates in Parkinson's disease. The present study aimed to investigate the role of dopaminergic denervation of STN in the origin of levodopa-induced dyskinesias. Rats were distributed in four groups which were concomitantly lesioned with 6-OHDA or vehicle (sham) in the STN and in the medial forebrain bundle (MFB) as follows: a) MFB-sham plus STN-sham, b) MFB-sham plus STN-lesion, c) MFB-lesion plus STN-sham, and d) MFB-lesion plus STN-lesion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!